CVOT Summit 2022 Report: new cardiovascular, kidney, and glycemic outcomes

Table 2 Key information of the EMPA-KIDNEY trial

EMPA-KIDNEY
Class & Cardiovascular (CV) outcomes	HR (95% CI)	p-value
Primary composite outcome
Progression of kidney disease or death from CV causes	0.72 (0.64–0.82)	< 0.001
Key secondary outcome
Hospitalization for heart failure or death from CV causes	0.84 (0.67–1.07)	0.15
Key secondary outcome
Hospitalization for any cause^a	0.86 (0.78–0.95)	0.003
Key secondary outcome
Death from any cause	0.87 (0.70–1.08)	0.21
Secondary outcome
Progression of kidney disease	0.71 (0.62–0.81)
Secondary outcome
Death from CV causes	0.84 (0.60–1.19)
Secondary outcome
End-stage kidney disease or death from CV causes^b	0.73 (0.59–0.89)

Adverse events^c	HR (95% CI)
Serious urinary tract infection	0.94 (0.64–1.37)
Serious hyperkalemia	0.83 (0.63–1.09)
Serious acute kidney injury	0.78 (0.60–1.00)
Serious dehydration	1.25 (0.73–2.14)
Severe hypoglycemia	1.00 (0.73–1.37)

^aThe analysis of hospitalizations for any cause included the first and all subsequent events, so only the rates are shown; 1611 hospitalizations occurred among 960 participants in the empagliflozin group, and 1895 hospitalizations occurred among 1035 participants in the placebo group
^bEnd-stage kidney disease was defined as the initiation of maintenance dialysis or receipt of a kidney transplant
^cSelected adverse events

ISSN: 1475-2840